PFG Private Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

PFG Private Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11	Closed	-$302	–	267
2024 Q4	$302	Hold	11	–	–	﹤0.01%	224
2024 Q3	$280	Hold	11	–	–	﹤0.01%	223
2024 Q2	$279	Buy	+11	New	+$301	﹤0.01%	226

Other funds holding BBIO

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PFG Private Wealth Management's BBIO Position: Q1 2025 in Review

PFG Private Wealth Management sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 11 shares — an estimated $302 sold.

PFG Private Wealth Management first reported a position in BBIO in Q2 2024 and held it in 3 quarters. The position peaked at $302 in Q4 2024. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

PFG Private Wealth Management reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
PFG Private Wealth Management sold 11 BridgeBio Pharma shares in Q1 2025, an estimated $302.
PFG Private Wealth Management first reported a position in BridgeBio Pharma in Q2 2024 and held it in 3 quarters.
PFG Private Wealth Management's BridgeBio Pharma position peaked at $302 in Q4 2024.
304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on PFG Private Wealth Management's 13F filing for Q1 2025, filed 13 May 2025.